The company is also registering the patent in Canada, US and Japan, it added. With its unique features, the innovation is expected to be the preferred option for all benzamidazole derivatives especially omeprazole, and lansaprazole in soft gel form, it said. With several drugs going off patent in the coming years, the invention is expected to provide several opportunities to the company to commercially exploit the invention, it added. Natco is now ensured exclusive use of the delivery system specified in the patent, it said. The company is also exploring the possibility of tie-ups for commercial exploitation of the patent, it added.










